CD274 and hepatocellular carcinoma: Antibodies to PD-L1/PD-1 have been approved for adjuvant therapy of HCC.15 Studies have also shown that the poor therapeutic effect of PD-1 adjuvant treatment is related to the increase of serum IL-6 concentration.